While gurus hold positions in these companies, the stock price and returns continue to fall. These are the worst-performing stocks over the last three months with a long-term presence in more than four gurus’ portfolio.
Bloomin Brands Inc. (BLMN, Financial) had a negative performance of -4% over the last three months. Despite this, four mutual funds are holding the stock with a total weight of 0.06% on their portfolios.
The company has a market cap of $1.92 billion and the stock is trading with a price-earnings (P/E) ratio of 34.45 and a forward P/E ratio of 12.95. The current price of $18.26 is 8.65% below its 52-week high and 22.47% above its 52-week low. Over the last 10 years, it has returned a gain of 47%. According to the DCF calculator, the company is overpriced by 222%.
Over the last five years, the company has reported a 0.3% decline in revenue and 10.90% decline in free cash flow. In contrast, the EBITDA and EPS grew 0.20% and 12.10%.
The return on equity (ROE) of 18.79% is ranked higher than 80% of other competitors. The return on assets (ROA) of -2.20% underperforms 62% of other companies in the Global Restaurants industry.
The largest shareholder among the gurus is Keeley Asset Management Corp. (Trades, Portfolio) with 1.25% of outstanding shares, followed by Richard Snow (Trades, Portfolio) with 0.31%, Steven Cohen (Trades, Portfolio) with 0.26% and Jim Simons (Trades, Portfolio) with 0.22%.
Finish Line Inc. (FINL, Financial) had a negative performance of -21% over the last three months. Regardless, four mutual funds are holding the stock with a total weight of 0.09% on their portfolios.
The company has a market cap of $727.65 million and the stock is trading with a forward P/E ratio of 12.47. The current price of $17.94 is 26.84% below its 52-week high and 8.40% above its 52-week low. Over the last 10 years, it has returned a gain of 40%. According to the DCF calculator, the stock is overpriced by 210%.
Over the last five years, the company has reported revenue growth of 13.40%, but a 4.90% decrease in EBITDA and a 12.30% decline in EPS.
The ROE of -1.08% and ROA of -0.58% are ranked lower than 74% of other competitors in the Global Specialty Retail industry.
John Hussman (Trades, Portfolio) is the largest gure shareholder with 0.62% of outstanding shares, followed by Cohen with 0.62%, Barrow, Hanley, Mewhinney & Strauss with 0.43% and Joel Greenblatt (Trades, Portfolio) with 0.28%.
Patterson Companies Inc. (PDCO, Financial) had a negative performance of -10% over the last three months. Despite this, four mutual funds are holding the stock with a total weight of 0.11% on their portfolios.
The company has a market cap of $4.19 billion. At the current price of $43, the stock is overpriced by 85% and is 15.20% below its 52-week high and 17.47% above its 52-week low. Over the last 10 years, it has returned a gain of 9%.
Over the last five years, the company reported a revenue gain of 11.70% and EBITDA growth of 2.50%. It reported a 1% decrease for EPS and a 15% decline for free cash flow.
The ROE of 14.78% and ROA of 5.87% are ranked higher than 76% of other competitors in the Global Medical Distribution industry.
The largest shareholder among the gurus is Mairs and Power (Trades, Portfolio) with 1.96% of outstanding shares, followed by Mario Gabelli (Trades, Portfolio) with 1.45%, Jerome Dodson (Trades, Portfolio) with 0.45% and Robert Olstein (Trades, Portfolio) with 0.36%.
Insys Therapeutics Inc. (INSY, Financial) had a negative performance of -24% over the last three months. Regardless, five mutual funds are holding the stock with a total weight of 0.12% on their portfolios.
The company has a market cap of $692.57 million and the stock is trading with a P/E ratio of 31.13 and a forward P/E ratio of 42.04. The price of $9.65 is 54.52% below its 52-week high and 10.92% above its 52-week low. Over the last 10 years, it has returned a loss of 72%. According to the DCF calculator, the company is overpriced by 188%.
Its ROE of 9.46% and ROA of 7.13% are ranked higher than 85% of other companies in the Global Biotechnology industry.
Cohen is the largest guru shareholder with 0.51% of outstanding shares, followed by Greenblatt with 0.46%, Simons with 0.37%, Lee Ainslie (Trades, Portfolio) with 0.28% and Paul Tudor Jones (Trades, Portfolio) with 0.02%.
Sally Beauty Holdings Inc. (SBH, Financial) had a negative performance of -11% over the last three months. Despite this, four mutual funds are holding the stock with a total weight of 0.13% on their portfolios.
The company has a market cap of $3.32 billion and the stock is now trading with a P/E ratio of 14.36 and a forward P/E ratio of 13.21. The current price of $23.26 is 29.37% below its 52-week high and 8.14% above its 52-week low. Over the last 10 years, it has returned a gain of 145%. According to the DCF calculator, the stock is undervalued with a 41% margin of safety.
Over the last five years, the company has reported revenue growth of 9%, 8% growth for EBITDA, 5.70% growth for EPS and 1.70% growth for free cash flow.
The ROA of 11.32% and return on capital (ROC) of 54.15% are ranked higher than 85% of other companies in the Global Specialty Retail industry.
The largest shareholder among the gurus is Gabelli with 0.66% of outstanding shares, followed by Cohen with 0.3%, Pioneer Investments (Trades, Portfolio) with 0.1% and Simons with 0.09%.
OPKO Health Inc. (OPK, Financial) had a negative performance of -18% over the last three months. Regardless, four mutual funds are holding the stock with a total weight of 0.13% on their portfolios.
The company has a market cap of $4.58 billion and the stock is now trading with a P/B ratio of 2.18. The current price of $8.40 is 32.35% below its 52-week high and 7.59% above its 52-week low. Over the last 10 years, it has returned a gain of 414%.
Over the last five years, the company has reported revenue growth of 48.50%, 49.20% growth for EBITDA and EPS growth of 29%.
The ROE of -0.49% and ROA of -0.35% are ranked lower than 78% of other companies in the Global Drug Manufacturers - Specialty and Generic industry.
Simons is the largest shareholder among the gurus with 0.25% of outstanding shares, followed by Greenblatt with 0.1%, Gabelli with 0.02% and Murray Stahl (Trades, Portfolio) with 0.01%.
Seattle Genetics Inc. (SGEN, Financial) had a negative performance of -11% over the last three months. Despite this, five mutual funds are holding the stock with a total weight of 0.16% on their portfolios.
The company has a market cap of $8.52 billion and the stock is now trading with a P/B ratio of 13.43. The current price of $62.88 is 20.17% below its 52-week high and 130.41% above its 52-week low. Over the last 10 years, it has returned a gain of 536%.
The company has reported revenue growth of 23.90%, 3.10% EBITDA growth and 2.40% growth for EPS over the last five years.
The ROE of -21.01% and ROA of -16.19% are ranked higher than 62% of other companies in the Global Biotechnology industry.
PRIMECAP Management (Trades, Portfolio) is the largest shareholder among the gurus with 9.35% of outstanding shares, followed by Columbia Wanger (Trades, Portfolio) with 0.54%, Ray Dalio (Trades, Portfolio) with 0.12%, Manning & Napier Advisors Inc. with 0.1% and Jones with 0.01%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
Start a free 7-day trial of Premium Membership to GuruFocus.
